<DOC>
	<DOCNO>NCT02192736</DOCNO>
	<brief_summary>Allogeneic mesenchymal trophic factor ( MTF ) human umbilical cord tissue-derived mesenchymal stem cell ( UC-MSC ) administer intra-nasally 20 patient safe useful procedure induce improvement pulmonary function quality life asthma patient .</brief_summary>
	<brief_title>Safety Feasibility Study Intranasal Mesenchymal Trophic Factor ( MTF ) Treatment Asthma</brief_title>
	<detailed_description>The propose study ass primary safety secondary efficacy endpoint allogeneic UC-MSC-derived MTF administer asthma patient . Each patient receive intra-nasal MTF per week period 4 week .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Signed consent form subject Male female Between 18 65 year old capability comprehend trial . Asthma diagnose physician least 1 year prior study enrollment Poorlycontrolled asthma study enrollment . Poorly control asthma define : chronic symptom , episodic exacerbation , persistent variable airway obstruction despite continued requirement shortacting beta 2agonists despite use high dos inhale steroid . Nonsmokers ( stop smoke least 1 year ago ) limit lifetime history smoking ( le 3 pack year history ) . Body mass index 1940 On stable dose inhale corticosteroid least 4 week prior study entry use rescue dose last 4 week . FEV1 &gt; 50 % predict Pregnant lactate woman Cognitively impaired adult Systemic steroid within 4 week prior enrollment Nonsteroidal antiinflammatory drug ( NSAIDs ) arthritis Current diagnosis polyposis sinusitis . Infection treat antibiotic within 4 week prior enrollment Immunization within 4 week prior enrollment Lung pathology asthma Other significant nonpulmonary comorbidities : coronary artery disease , peripheral vascular disease , cerebrovascular disease , congestive heart failure ejection fraction &lt; 50 % , liver disease elevate liver enzymes baseline , malignancy ( exclude nonmelanoma skin cancer ) , AIDS , renal failure serum creatinine &gt; 3.0 , disorder require steroid treatment vasculitis , lupus , rheumatoid arthritis Illicit drug use within past year Current/active upper respiratory infection ( URI ) ( active URI , wait asymptomatic 1 week enroll ) Asthma exacerbation within 4 week prior enrollment ( include ER , urgent care , hospital visit due asthma result increase asthmarelated medication ) Undergoing evaluation sleep apnea , plan institute treatment sleep apnea ( patient stable treatment regimen sleep apnea last 3 month prior enrollment allow participate ) Clinically significant abnormality present screen 12lead electrocardiogram Women childbearing potential use oral contraceptive willing use second method contraception study Participation another clinical study within 4 week prior enrollment Subject sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>umbilical cord</keyword>
	<keyword>mesenchymal</keyword>
	<keyword>stem cell</keyword>
	<keyword>trophic factor</keyword>
</DOC>